Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T06:49:48.542Z Has data issue: false hasContentIssue false
  • English
  • Français

Gastrointestinal Tract Colonization With Fluoroquinolone-Resistant Escherichia coli in Hospitalized Patients: Changes Over Time in Risk Factors for Resistance

Published online by Cambridge University Press:  02 January 2015

Ebbing Lautenbach ,
Joshua P. Metlay ,
Mark G. Weiner ,
Warren B. Bilker ,
Pam Tolomeo ,
Xiangqun Mao ,
Irving Nachamkin  and
Neil O. Fishman
Ebbing Lautenbach*
Affiliation:
Divisions of Infectious Diseases, Philadelphia, Pennsylvania Department of Medicine, the Department of Biostatistics and Epidemiology, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania
Joshua P. Metlay
Affiliation:
General Internal Medicine, Philadelphia, Pennsylvania Department of Medicine, the Department of Biostatistics and Epidemiology, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania University of Pennsylvania School of Medicine, and the Department of Veterans Affairs, Philadelphia, Pennsylvania
Mark G. Weiner
Affiliation:
General Internal Medicine, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania
Warren B. Bilker
Affiliation:
Department of Medicine, the Department of Biostatistics and Epidemiology, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania
Pam Tolomeo
Affiliation:
Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania
Xiangqun Mao
Affiliation:
Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania
Irving Nachamkin
Affiliation:
Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania
Neil O. Fishman
Affiliation:
Divisions of Infectious Diseases, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, Philadelphia, Pennsylvania
*
University of Pennsylvania School of Medicine, Center for Clinical Epidemiology and Biostatistics, 825 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

The prevalence of fluoroquinolone (FQ) resistance in Escherichia coli has increased markedly in recent years. Despite the important role of gastrointestinal tract colonization with FQ-resistant E. coli (FQREC), the prevalence of and risk factors for FQREC colonization among the general hospitalized patient population have not been described, to our knowledge. The objective of this study was to identify the prevalence of and risk factors for FQREC colonization among hospitalized patients.

Design.

Three-year case-control study. Case patients (ie, all subjects with FQREC colonization) were compared with control patients (ie, all subjects without FQREC colonization).

Setting.

Two large medical centers within an academic health system.

Participants.

All patients hospitalized at the 2 study hospitals.

Main Outcome Measure.

Three annual fecal surveillance surveys were conducted. All patients colonized with FQREC (levofloxacin minimum inhibitory concentration, ≥ 8 μg/mL) were identified.

Results.

Of the 774 subjects, 89 (11.5%) were colonized with FQREC. Although there was a significant association between prior FQ use and FQREC colonization on bivariable analysis (odds ratio [OR], 2.02 [95% confidence interval {CI}, 1.14–3.46]; P = .01), there was statistically significant effect modification by year of study (P = .005). In multivariable analyses, after controlling for the hospital and for the duration of hospitalization prior to sampling, the association between FQ use and FQREC colonization was as follows: adjusted OR (aOR), 0.97 (95% CI, 0.29–3.23) in 2002; aOR, 1.41 (95% CI, 0.57–3.50) in 2003; and aOR, 9.87 (95% CI, 3.67–26.55) in 2004.

Conclusions.

The association between prior FQ use and FQREC colonization varied significantly by study year, suggesting that the clinical epidemiology of resistant organisms may change over time. Furthermore, in the context of recent work showing significant changes in FQREC prevalence as well as changes in FQ resistance mechanisms (specifically, efflux overexpression) over the same time period, these results suggest a previously unrecognized complexity in the relationship between the clinical and molecular epidemiology of FQ resistance.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 1 , January 2009 , pp. 18 - 24
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Hooper, DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243–254.Google Scholar
2.Lee, YL, Cesario, T, McCauley, V, Flionis, L, Pax, A, Thrupp, L. Low-level colonization and infection with ciprofloxacin-resistant gram-negative bacilli in a skilled nursing facility. Am J Infect Control 1998;26:552–557.Google Scholar
3.Linder, JA, Huang, ES, Steinman, MA, Gonzales, R, Stafford, RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259–268.CrossRefGoogle ScholarPubMed
4.Lautenbach, E, Strom, BL, Nachamkin, I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients (1989-2000): differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655–662.Google Scholar
5.Neuhauser, MM, Weinstein, RA, Rydman, R, Danziger, LH, Karam, G, Quinn, JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003;289:885–888.Google Scholar
6.Lautenbach, E, Metlay, JP, Bilker, WB, Edelstein, PH, Fishman, NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: role of inadequate empiric antimicrobial therapy. Clin Infect Dis 2005;41:923–929.Google Scholar
7.Lautenbach, E, Strom, BL, Bilker, WB, Patel, JB, Edelstein, PH, Fishman, NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288–1294.Google Scholar
8.Paterson, DL, Mulazimoglu, L, Casellas, JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473–478.CrossRefGoogle ScholarPubMed
9.Bettelheim, KA. The genus Escherichia. In: Balows, A, Truper, HG, Dworkin, M, Harder, W, Schleifer, KH, eds. The Prokaryotes: a handbook on the biology of bacteria: ecophysiology, isolates, identification, applications. New York: Springer-Verlag; 1991.Google Scholar
10.Janda, JM, Abbott, SL. The Enterobacteria. Philadelphia: Lippincott-Raven;1998.Google Scholar
11.Arbeit, RD, Arthur, M, Dunn, R, Kim, C, Selander, RK, Goldstein, R. Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect Dis 1990;161:230–235.CrossRefGoogle ScholarPubMed
12.Brumfitt, W. Progress in understanding urinary infections. J Antimicrob Chemother 1991;27:9–22.CrossRefGoogle ScholarPubMed
13.Oethinger, M, Jellen-Ritter, AS, Conrad, S, Marre, R, Kern, WV. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998;26:379–384.Google Scholar
14.Lautenbach, E, Fishman, NO, Metlay, JP, et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006;194:79–85.Google Scholar
15.Maslow, JN, Lee, B, Lautenbach, E. Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerg Infect Dis 2005;11:889–894.Google Scholar
16.Baum, HV, Franz, U, Geiss, HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000;28:278–281.Google Scholar
17.Richard, P, Delangle, MH, Raffi, F, Espaze, E, Richet, H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001;32:162–166.CrossRefGoogle ScholarPubMed
18.Aparicio, JR, Such, J, Pascual, S, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999;31:277–283.Google Scholar
19.Zaidi, MB, Zamora, E, Diaz, P, Tollefson, L, Fedorka-Cray, PJ, Headrick, ML. Risk factors for fecal quinolone-resistant Escherichia coli in Mexican children. Antimicrob Agents Chemother 2003;47:1999–2001.Google Scholar
20.Lautenbach, E, Harris, AD, Perencevich, EN, Nachamkin, I, Tolomeo, P, Metlay, JP. Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract. Antimicrob Agents Chemother 2005;49:798–800.CrossRefGoogle ScholarPubMed
21.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 16th informational supplement. Wayne, PA: CLSI; 2006:M100-S16.Google Scholar
22.Barton, TD, Fishman, NO, Weiner, MG, LaRosa, LA, Lautenbach, E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005;26:93–99.Google Scholar
23.Quain, RD, Barton, TD, Fishman, NO, Weiner, MG, Lautenbach, E. Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int J Antimicrob Agents 2005;26:327–330.CrossRefGoogle ScholarPubMed
24.Gasink, LB, Fishman, NO, Weiner, MG, Nachamkin, I, Bilker, WB, Lautenbach, E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;199:526.e19-25.Google Scholar
25.MacAdam, H, Zaoutis, TE, Gasink, LB, Bilker, WB, Lautenbach, E. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorizing prior antibiotic use. Int J Antimicrob Agents 2006;28:325–332.Google Scholar
26.Deyo, RA, Cherkin, DC, Ciol, MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.Google Scholar
27.Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold; 1982.Google Scholar
28.Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.Google Scholar
29.Hosmer, DO, Lemeshow, SL. Applied logistic regression. New York: Wiley and Sons; 1989.Google Scholar
30.Sun, GW, Shook, TL, Kay, GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907–916.Google Scholar
31.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125–137.Google Scholar
32.Jacoby, GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120–S126.Google Scholar
33.Hooper, DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337–341.Google Scholar
34.Wang, H, Dzink-Fox, JL, Chen, M, Levy, SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001;45:1515–1521.Google Scholar
35.White, DG, Goldman, JD, Demple, B, Levy, SB. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol 1997;179:6122–6126.Google Scholar
36.Lautenbach, E, Fishman, NO, Bilker, WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–2477.Google Scholar
37.Lautenbach, E, Larosa, LA, Kasbekar, N, Peng, HP, Maniglia, RJ, Fishman, NO. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003;163:601–605.Google Scholar
38.Poole, K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 2000;44:2233–2241.Google Scholar
39.Paterson, DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st century approach. Clin Infect Dis 2002;34:1564–1567.Google Scholar
40.Baquero, F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resistance Updates 2001;4:93–105.Google Scholar
41.Courvalin, P, Trieu-Cuot, P. Minimizing potential resistance: the molecular view. Clin Infect Dis 2001;33(Suppl 3):S138–S146.Google Scholar